MedPAC Seeks Stakeholder Input On Medicare “Least Costly Alternative” Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments by members of the Medicare Payment Advisory Commission at a recent meeting suggest an opportunity for pharmaceutical industry stakeholders to help frame the discussion of Medicare value-based payment approaches for Part B drugs.